News Wire

Researchers at Merck have found a way to return antibacterial efficacy to agents that have lost their ability to kill certain types of bacteria. In a paper published in Science Translational Medicine, the team describes a search for molecules capable of interfering with one of the main defense mechanisms…
Large health systems and hospital operators are reporting sliding profits, revenue, and income because of value-based care, according to an article posted on the HealthLeaders Media website. A turnaround is expected, however, once the industry more fully adopts the value-based model. Kaiser Foundation…
Experts on the Zika virus outbreak have agreed on three top priorities for research into medical products, the World Health Organization (WHO) has reported. The WHO warned, however, that vaccine trials may come too late for the current outbreak. The top research priorities are: 1) tests for other viruses,…
Medicare plans to test new ways to pay for prescription drugs given in doctors’ offices and hospital outpatient centers, according to a report from Kaiser Health News. Under a two-part proposal, regulators aim to reduce what some economists and policy experts say are financial incentives for doctors…
Cepheid has received clearance from the FDA to market Xpert Carba-R, a qualitative in vitro diagnostic test for rapid, accurate, and reproducible identification of five distinct families of carbapenem resistance genes that together represent the most common carbapenemases identified globally, including…
The U.S. Preventive Services Task Force (USPSTF) is seeking comments on a draft recommendation statement on screening for latent tuberculosis infection (LTBI) in adults. The task force recommends screening for LTBI in adults at increased risk. The USPSTF last issued a recommendation on screening for…
The FDA has lifted its partial clinical hold on the investigational new drug (IND) application for pidilizumab (MDV9300, Medivation, Inc.) in hematologic malignancies and has confirmed that the pivotal phase 2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well…
Researchers at Columbia University’s Mailman School of Public Health, with colleagues at the White House Social and Behavioral Sciences Team, the Massachusetts Institute of Technology, and the Centers for Medicare and Medicaid Services (CMS), have conducted a randomized trial of informative letters…
French researchers have linked the Zika virus to the paralyzing disorder myelitis, according to a report posted on the Medical Xpress website. Zika virus infection is already suspected of causing microcephaly and brain damage in infants and Guillain–Barré syndrome in adults. A 15-year-old girl diagnosed…
Retail clinics, long seen as an antidote to more-expensive doctors’ offices and emergency rooms, may actually boost medical spending by leading consumers to get more care, according to a report from Kaiser Health News. A new study published in the March issue of Health Affairs has shown…
The National Osteoporosis Foundation (NOF), in a joint effort with the Pharmaceutical Research and Manufacturers of America, has released a report on new therapies being developed for the treatment of osteoporosis. The publication examines the nationwide effects of the disease and explores how new medications…
The International Consortium for Health Outcomes Measurement (ICHOM) has selected ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, to advance value-based health care through the launch of a global health care…
In an international study, researchers have found that the HOSPITAL score, an acronym created to identify the variables associated with hospital readmissions, successfully predicted patients at high risk of a 30-day potentially avoidable readmission. The researchers believe this score may help identify…
The FDA has given the nod to Idelvion (coagulation factor IX [recombinant], albumin fusion protein, CSL Behring), a long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of patients with hemophilia B. Idelvion is the first factor IX therapy…
New safety and efficacy data have shown that the risk–benefit profile generated through pivotal studies of mepolizumab (Nucala, GlaxoSmithKline) was maintained over 52 weeks. The study also demonstrated the exacerbation risk reduction, asthma control improvement, and oral corticosteroid dose reduction…

Pages